MEDIR is a specialty pharmaceutical company, seeking to address the areas of high unmet medical needs in: 1. inducing mild sedation in a safe, convenient and needlefree way; and 2. offering a treatment for acute epileptic seizure control outside a hospital setting, that is fast, efficacious and easy adminstered.
The company has developed nasal sprays containing midazolam, a compound that currently needs to be administered by intravenous injection for predicitive results. MEDIR is in the process of generating the CMC-, non-clinical- and clinical dataset, necessary to obtain marketing authorisation for the nasal spray product.

Commercialization rights will be out-licensed to partners. Nasal midazolam is not registered anywhere in the world yet.